Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.

ABSTRACT: The introduction of novel immunotherapies has transformed the treatment landscape in multiple myeloma (MM). The addition of these agents has significantly improved patient outcomes; however, MM remains largely incurable, with heavily pretreated patients suffering from shorter survival times. To address this unmet need, the focus has shifted toward novel mode of action therapies, such as bispecific antibodies (BsAb), which simultaneously bind to immune effector cells and myeloma cells. Currently, there are several T cell-redirecting BsAb being developed that target BCMA, GPRC5D, and FcRH5. These BsAb show impressive clinical activity for the relapsed/refractory population targeted and will likely become an essential part of MM treatment protocols in the future. In this podcast, the authors

SUBMITTER: Landgren O 

PROVIDER: S-EPMC10329949 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature